There is no cure for herpes virus infections. Antiviral drugs are available that have some effect on lessening the symptoms and decreasing the length of herpes outbreaks. There is evidence that some may also prevent future outbreaks. These antiviral drugs work by interfering with the reproduction of the viruses and are most effective when taken as early in the infection as possible. For the best results, drug treatment should begin during the prodrome stage before blisters are visible. Depending on the length of the outbreak, drug treatment could continue for up to ten days.
You may have concerns about how genital herpes will impact your overall health, sex life, and relationships. It is best for you to talk to a health care provider about those concerns, but it also is important to recognize that while herpes is not curable, it can be managed with medication. Daily suppressive therapy (., daily use of antiviral medication) for herpes can also lower your risk of spreading genital herpes to your sex partner. Be sure to discuss treatment options with your healthcare provider. Since a genital herpes diagnosis may affect how you will feel about current or future sexual relationships, it is important to understand how to talk to sexual partners about STDs .
Its only indication that has received regulatory approval worldwide is cytomegalovirus retinitis.   Cidofovir has also shown efficacy in the treatment of aciclovir -resistant HSV infections.  Cidofovir has also been investigated as a treatment for progressive multifocal leukoencephalopathy with successful case reports of its use.  Despite this, the drug failed to demonstrate any efficacy in controlled studies.  Cidofovir might have anti- smallpox efficacy and might be used on a limited basis in the event of a bioterror incident involving smallpox cases.  Brincidofovir , a cidofovir derivative with much higher activity against smallpox that can be taken orally has been developed.  It has inhibitory effects on varicella-zoster virus replication in vitro although no clinical trials have been done to date, likely due to the abundance of safer alternatives such as aciclovir .  Cidofovir shows anti- BK virus activity in a subgroup of transplant recipients.  Cidofovir is being investigated as a complementary intralesional therapy against papillomatosis caused by HPV .